Analysts Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Price Target at $14.28

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have earned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $14.2750.

NAGE has been the subject of a number of research analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a report on Wednesday, October 8th. Canaccord Genuity Group lowered their price target on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th.

Niagen Bioscience Stock Down 0.6%

Shares of NASDAQ NAGE opened at $6.52 on Monday. The company has a market capitalization of $520.34 million, a PE ratio of 27.17 and a beta of 2.35. The stock’s 50 day moving average price is $6.68 and its 200-day moving average price is $8.56. Niagen Bioscience has a twelve month low of $5.17 and a twelve month high of $14.69.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Niagen Bioscience had a return on equity of 24.13% and a net margin of 16.38%.The business had revenue of $33.99 million for the quarter, compared to analyst estimates of $31.30 million.

Insider Activity at Niagen Bioscience

In other news, CFO Ozan Pamir purchased 4,465 shares of the business’s stock in a transaction dated Friday, November 14th. The stock was bought at an average price of $6.81 per share, for a total transaction of $30,406.65. Following the purchase, the chief financial officer owned 7,372 shares of the company’s stock, valued at $50,203.32. The trade was a 153.59% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 9.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Niagen Bioscience

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC raised its position in shares of Niagen Bioscience by 5.7% in the fourth quarter. SG Americas Securities LLC now owns 54,649 shares of the company’s stock valued at $348,000 after purchasing an additional 2,950 shares during the period. Miller Global Investments LLC purchased a new position in Niagen Bioscience in the 4th quarter valued at approximately $120,000. JPMorgan Chase & Co. purchased a new position in Niagen Bioscience in the 3rd quarter valued at approximately $3,678,000. NewEdge Advisors LLC bought a new stake in Niagen Bioscience during the 3rd quarter valued at $205,000. Finally, Caxton Associates LLP purchased a new stake in shares of Niagen Bioscience during the third quarter worth $274,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.